(S)-2-(4-Benzyloxycarbonylamino-butyrylamino)-3-(1H-indol-3-yl)-propionic acid | 406726-81-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (S)-2-(4-Benzyloxycarbonylamino-butyrylamino)-3-(1H-indol-3-yl)-propionic acid
• 英文别名: (2S)-3-(1H-indol-3-yl)-2-[4-(phenylmethoxycarbonylamino)butanoylamino]propanoic acid
• CAS: 406726-81-6
• 化学式: C₂₃H₂₅N₃O₅
• 分子量: 423.469
• InChiKey: BIZNRPAMKKIHIP-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  31
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,5-dioxopyrrolidin-1-yl 4-(((benzyloxy)carbonyl)amino)butanoate 以98%的产率得到(S)-2-(4-Benzyloxycarbonylamino-butyrylamino)-3-(1H-indol-3-yl)-propionic acid
  参考文献：
  名称：

  Carbamic acid compounds comprising an amide linkage as hdac inhibitors

  摘要：

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。

  公开号：

  US20040092598A1

文献信息

• CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS
  申请人：Watkins Clare J.

  公开号：US20110105572A1

  公开（公告）日：2011-05-05

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is a C 5-20 heteroaryl or C 5-20 carboaryl group and is optionally substituted; Q 1 is a C 2-7 alkylene group having a backbone of at least 2 carbon atoms, and is optionally substituted; J is —N(R 1 )C(═O)— or —C(═O)N(R 1 )—; R 1 is hydrogen, C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; and, Q 2 is C 1-7 alkylene, C 5-20 arylene, C 5-20 arylene-C 1-7 alkylene, or C 1-7 alkylene-C 5-20 arylene having a backbone of at least 3 carbon atoms, and is optionally substituted; and pharmaceutically acceptable salts thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to treat proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性碳酰胺酸化合物，其抑制HDAC活性，并具有以下公式：其中：A是C5-20杂环芳基或C5-20羰基芳基基团，并可选择性地取代；Q1是具有至少2个碳原子的C2-7烷基链，可选择性地取代；J是-N（R1）C（═O）-或-C（═O）N（R1）-；R1是氢，C1-7烷基，C3-20杂环芳基或C5-20芳基；Q2是具有至少3个碳原子的C1-7烷基链，C5-20芳基链，C5-20芳基链-C1-7烷基链，或C1-7烷基链-C5-20芳基链，并可选择性地取代；以及其药学上可接受的盐。本发明还涉及包含这种化合物的制药组合物，以及使用这种化合物和组合物在体内外抑制HDAC，例如治疗增殖性疾病，如癌症和牛皮癣。
• Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
  申请人：TopoTarget UK Limited

  公开号：EP1598067A1

  公开（公告）日：2005-11-23

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR1C(=O)- and -C(=O)NR1-; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof, for use in the treatment of parasitic infections, such as malaria.

  本发明涉及某些抑制 HDAC 活性的活性氨基甲酸化合物，它们具有下式： 其中A是芳基；Q1是具有至少2个碳原子骨架的芳基领导基团；J是选自-NR1C(＝O)-和-C(＝O)NR1-的酰胺连接；R1是氨基取代基；Q2是酸领导基团；及其药学上可接受的盐、溶液剂、酰胺、酯、醚、化学保护形式和原药，用于治疗寄生虫感染，如疟疾。
• US7569724B2
  申请人：——

  公开号：US7569724B2

  公开（公告）日：2009-08-04
• US7880020B2
  申请人：——

  公开号：US7880020B2

  公开（公告）日：2011-02-01
• [EN] CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS<br/>[FR] COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UN ENCHAINEMENT AMIDE COMME INHIBITEURS HDAC
  申请人：PROLIFIX LTD

  公开号：WO2002026696A1

  公开（公告）日：2002-04-04

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR1C(=O)- and -C(=O)NR1-; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.